Skip to content

Non-invasive Evaluation of the Benefits of Gastric Cancer Chemotherapy Combined with Immunotherapy Based on Deep Learning and CT Radiomics

Non-invasive Evaluation of the Benefits of Gastric Cancer Chemotherapy Combined with Immunotherapy Based on Deep Learning and CT Radiomics

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600122856
Enrollment
Unknown
Registered
2026-04-20
Start date
2023-10-25
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Gastric cancer

Interventions

Training group:None
Validation group:None

Sponsors

Henan Provincial People's Hospita,medical
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. 18 years = age = 80 years 2.Patients with advanced or advanced gastric cancer who have received 2 or more cycles of chemotherapy (regimen is not required) combined with immune checkpoint inhibitors (PD-1 inhibitors or PDL1 inhibitors) in the first-line treatment before surgery; 3. Pathological results confirmed gastric cancer; 4.Complete abdominal enhancement CT imaging data within 30 days before immunotherapy; 5.Complete clinicopathological data, and postoperative pathological stage according to version 8 AJCC was stage II-III; 6.No history of other malignant tumors;

Exclusion criteria

Exclusion criteria: 1. The primary lesion could not be found on CT; 2.The patient had primary tumors in other parts; 3.The patient's clinical data were incomplete; 4.The quality of CT images was unsatisfactory.

Design outcomes

Primary

MeasureTime frame
Tumor Retreat after Immunotherapy;

Countries

China

Contacts

Public ContactJunmeng Li

Henan Provincial People's Hospita,medical

lijunmeng001@163.com+86 371 6558 0425

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 1, 2026